Search results
Results From The WOW.Com Content Network
Novartis. / 47.5744252; 7.5764914. Pharmaceutical drugs, generic drugs, over-the-counter drugs, vaccines, diagnostics, contact lenses, animal health ( list...) Novartis AG is a Swiss multinational pharmaceutical corporation based in Basel, Switzerland. Consistently ranked in the global top five, Novartis is one of the largest pharmaceutical ...
The Novartis Foundation was a scientific and educational charity, formed in 1949 by the Swiss company Ciba, now Novartis, and dissolved in 2008. It was the direct successor to the Ciba Foundation, and the changed name (Novartis Foundation) reflected the new name of Ciba, after merging with Sandoz. The Foundation was the brainchild of Robert ...
Jimenez joined Novartis in 2007 as Division Head of Novartis Pharmaceutical and was named CEO in 2010 by his predecessor and Chairman Daniel Vasella. [8] During his time at Novartis, Jimenez increasingly applied standard business metrics to pharma cash flow, purchasing and competitive bidding, confident that his experience in consumer goods ...
Vasant "Vas" Narasimhan (born August 26, 1976) is an American physician and the chief executive officer of Novartis. He succeeded Joseph Jimenez who left Novartis in 2018. He briefly worked at McKinsey before joining Novartis in 2005, where he has held a range of leadership roles, including Global Head of Development for Novartis Vaccines and Global Head of Drug Development & Chief Medical ...
Sandoz Group AG is a Swiss company that focuses on generic pharmaceuticals and biosimilars. [4] Prior to October 2023, it was part of a division of Novartis that was established in 2003, when Novartis united all of its generics businesses under the name Sandoz. Before this, the company existed as an independent pharmaceutical manufacturer until ...
The treatment was developed by a group headed by Carl H. June and co-invented by Michael C. Milone at the University of Pennsylvania, and is licensed to Novartis. [16] In April 2017, tisagenlecleucel received breakthrough therapy designation by the U.S. Food and Drug Administration (FDA) for the treatment of relapsed or refractory diffuse large ...
Chiron Corporation ( / ˈkaɪrɒn / KY-ron) [1] was an American multinational biotechnology firm founded in 1981, based in Emeryville, California, that was acquired by Novartis on April 20, 2006. It had offices and facilities in eighteen countries on five continents. Chiron's business and research was in three main areas: biopharmaceuticals ...
Nilotinib. Nilotinib, sold under the brand name Tasigna marketed worldwide by Novartis, is a medication used to treat chronic myelogenous leukemia (CML) which has the Philadelphia chromosome. [4] It may be used both in initial cases of chronic phase CML as well as in accelerated and chronic phase CML that has not responded to imatinib.